MX2016004441A - Tratamiento del cancer con una combinacion de plinabulina y taxano. - Google Patents
Tratamiento del cancer con una combinacion de plinabulina y taxano.Info
- Publication number
- MX2016004441A MX2016004441A MX2016004441A MX2016004441A MX2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A
- Authority
- MX
- Mexico
- Prior art keywords
- plinabulin
- combination
- taxane
- taxane compound
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 229940123237 Taxane Drugs 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title abstract 4
- 229950011498 plinabulin Drugs 0.000 title abstract 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
- -1 taxane compound Chemical class 0.000 abstract 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención proporciona un método de tratamiento del cáncer novedoso en el cual la plinabulina (t-butil-deshidrofenilhistina o NPI-2358) y un compuesto de taxano (como el docetaxel) son usados en combinación. Nuestro estudio ha mostrado que la combinación óptima de inyección de plinabulina después del compuesto de taxano tiene eficacia mejorada inesperada en poblaciones de tumores grandes en modelos con animales y en pacientes con cáncer NSCLC en comparación con el tratamiento con compuesto de taxano solo. Además, esta combinación óptima puede alcanzar un efecto inesperadamente seguro en la disminución de los efectos laterales insoportables, incluyendo la disminución en sus tasas neutropenias en todos los grados y disminución del uso de G-CFS en pacientes con cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004441A true MX2016004441A (es) | 2016-10-28 |
| MX384751B MX384751B (es) | 2025-03-14 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004441A MX384751B (es) | 2013-10-11 | 2013-10-11 | Tratamiento del cáncer con una combinación de plinabulina y taxano. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (es) |
| EP (1) | EP3076972B1 (es) |
| JP (1) | JP6411523B2 (es) |
| KR (1) | KR102225371B1 (es) |
| CN (1) | CN105705148B (es) |
| AU (1) | AU2013402794B2 (es) |
| BR (1) | BR112016007946A2 (es) |
| CA (1) | CA2926771C (es) |
| DK (1) | DK3076972T3 (es) |
| ES (1) | ES2902665T3 (es) |
| IL (1) | IL244984B (es) |
| MX (1) | MX384751B (es) |
| MY (1) | MY185650A (es) |
| NZ (1) | NZ719049A (es) |
| RU (1) | RU2662298C2 (es) |
| SG (1) | SG11201602637QA (es) |
| WO (1) | WO2015051543A1 (es) |
| ZA (1) | ZA201602380B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016130839A1 (en) * | 2015-02-12 | 2016-08-18 | Beyondspring Pharmaceuticals, Inc. | Use of plinabulin in combination with immune checkpoint inhibitors |
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| AU2016229295B2 (en) * | 2015-03-06 | 2021-11-04 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| JP6969848B2 (ja) | 2015-07-13 | 2021-11-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリン組成物 |
| BR112018016054A2 (pt) | 2016-02-08 | 2019-02-12 | Beyondspring Pharmaceuticals, Inc. | composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo |
| RU2760348C2 (ru) * | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| WO2018144764A1 (en) * | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
| DK3595653T3 (da) * | 2017-03-13 | 2023-04-17 | Beyondspring Pharmaceuticals Inc | Sammensætninger af plinabulin og anvendelse heraf |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| CN112135614A (zh) * | 2018-01-24 | 2020-12-25 | 大连万春布林医药有限公司 | 通过施用普那布林减少血小板减少症的组合物和方法 |
| KR20200116477A (ko) * | 2018-02-01 | 2020-10-12 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법 |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| US20230035763A1 (en) * | 2018-11-14 | 2023-02-02 | BeyondSpring Pharnaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| JP2022552011A (ja) * | 2019-10-15 | 2022-12-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 鉄障害を処置するための方法及び組成物 |
| CA3215047A1 (en) * | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| CN100540548C (zh) | 2002-08-02 | 2009-09-16 | 尼瑞斯药品公司 | 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成 |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| AU2005212399B2 (en) * | 2004-02-04 | 2011-09-22 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| AU2014244083B2 (en) | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2662298C2 (ru) | 2018-07-25 |
| IL244984B (en) | 2022-05-01 |
| WO2015051543A8 (en) | 2016-04-21 |
| IL244984A0 (en) | 2016-05-31 |
| BR112016007946A2 (pt) | 2017-09-12 |
| DK3076972T3 (da) | 2022-01-03 |
| RU2016112608A (ru) | 2017-11-16 |
| MY185650A (en) | 2021-05-27 |
| EP3076972A4 (en) | 2017-12-20 |
| US10596169B2 (en) | 2020-03-24 |
| US20160250209A1 (en) | 2016-09-01 |
| AU2013402794A1 (en) | 2016-05-12 |
| KR20160078987A (ko) | 2016-07-05 |
| CN105705148A (zh) | 2016-06-22 |
| EP3076972B1 (en) | 2021-10-06 |
| CN105705148B (zh) | 2021-03-23 |
| JP6411523B2 (ja) | 2018-10-24 |
| KR102225371B1 (ko) | 2021-03-10 |
| JP2016536352A (ja) | 2016-11-24 |
| SG11201602637QA (en) | 2016-05-30 |
| AU2013402794B2 (en) | 2020-02-27 |
| WO2015051543A1 (en) | 2015-04-16 |
| MX384751B (es) | 2025-03-14 |
| US20200281921A1 (en) | 2020-09-10 |
| ZA201602380B (en) | 2022-05-25 |
| ES2902665T3 (es) | 2022-03-29 |
| CA2926771C (en) | 2022-07-05 |
| EP3076972A1 (en) | 2016-10-12 |
| CA2926771A1 (en) | 2015-04-16 |
| NZ719049A (en) | 2020-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004441A (es) | Tratamiento del cancer con una combinacion de plinabulina y taxano. | |
| ECSP24031979A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| CL2016000373A1 (es) | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| MX2021013520A (es) | Antagonistas de union al eje pd-1 y taxanos para usarse en el tratamiento de cancer. | |
| CL2016002798A1 (es) | Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón. | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| UY36075A (es) | Derivados de tubulisina | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| MX393818B (es) | Terapias de combinación para el tratamiento de cáncer. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| AR089993A1 (es) | Macrociclos peptidomimeticos | |
| MX382017B (es) | Metodos para el tratamiento de cancer pancreatico. | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| SV2017005373A (es) | Inhibidores de la proteína quinasa c y métodos de su uso | |
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| CO2019000753A2 (es) | Métodos para tratar el cáncer de próstata | |
| CL2015000715A1 (es) | Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion | |
| EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
| EA201690085A1 (ru) | Полимерные наночастицы доцетаксела для лечения рака |